目的：探讨帕金森药物治疗与高同型半胱氨酸血症的关系。方法选取2012年3月—2014年4月入该院就诊帕金森患者70例，随机分为两组，各35例，一组采取左旋多巴制剂药物治疗，即左旋多巴组，一组采取抗胆碱药物治疗，即抗胆碱组；另选取35例未进行药物治疗的帕金森患者和35例健康者作为对照，即未治疗组和健康组。分析比较三组患者同型半胱氨酸水平变化情况。结果左旋多巴组患者的同型半胱氨酸水平明显高于抗胆碱组和未治疗组，相比较差别具有统计学意义（P<0.05)；抗胆碱组患者同型半胱氨酸水平与未治疗组无明显差异，两组相比较差别无统计学意义（P>0.05)；左旋多巴组、抗胆碱组和未治疗组患者体内的同型半胱氨酸水平均显著高于健康组，相比较差异无统计学意义（P>0.05)。结论通过研究可知，高同型半胱氨酸是帕金森病的危险因素之一，帕金森疾病药物治疗中，左旋多巴制剂治疗可明显提升患者同型半胱氨酸水平，为帕金森药物治疗提供安全可靠的信息，值得临床推荐应用。%Objective To investigate the relationship between Parkinsonˊs medication with high homocysteine. Methods March 2012-April 2014 into our hospital 40 cases of Parkinsonˊs patients were randomly divided into two groups,each of 20 cases. A group taking medication levodopa,is levodopa group. A group to take anticholinergic medication that is anticholinergic group;an-other 20 cases of Parkinsonˊs patients and 20 healthy subjects did not carry out medical treatment as a control group and healthy group . Analysis and comparison of homocysteine ??levels in three groups of patients situation. Results Homocysteine levels in patients with levodopa group was significantly higher than anticholinergic group and the untreated group,the difference was statis-tically significant (P<0.05);compared with untreated group,anticholinergic homocysteine levels in patients had no significant dif-ference in the two groups,there was statistically significant compared to no less (P>0.05);levodopa group, anticholinergic group and untreated patients homocysteine levels were significantly higher than the healthy group, poor no statistically significant (P>0.05) compared to. Conclusion The study shows that high homocysteine is a risk factor for Parkinsonˊs not one of the drug treat-ment of Parkinsonˊs disease levodopa therapy can significantly improve the levels of homocysteine in patients,drug therapy for Parkinsonˊs safe and reliable information,it is recommended clinical applications.
展开▼
